Comparison between Dev Labtech Venture IPO and Sotac Pharmaceuticals IPO.
Dev Labtech Venture IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Sotac Pharmaceuticals IPO is a SME Bookbuilding proposed to list at NSE SME.
| Dev Labtech Venture IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Beeline Capital Advisors Pvt.Ltd. | Beeline Capital Advisors Pvt.Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | Sunflower Broking Pvt.Ltd. | Sunflower Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Dev Labtech Venture IPO is up to ₹10.65 Cr whereas the issue size of the Sotac Pharmaceuticals IPO is up to ₹31.64 Cr. The final issue price of Dev Labtech Venture IPO is ₹51.00 per share and of Sotac Pharmaceuticals IPO is ₹111.00 per share.
| Dev Labtech Venture IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹105.00 per share | |
| Issue Price (Upper) | ₹111.00 per share | |
| Issue Price (Final) | ₹51.00 per share | ₹111.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 1200 shares |
| Fresh Issue Size | 20,88,000 shares | 28,50,000 shares |
| Fresh Issue Size (Amount) | up to ₹10.65 Cr | up to ₹31.64 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 20,88,000 shares | 28,50,000 shares |
| Issue Size Total (Amount) | up to ₹10.65 Cr | up to ₹31.64 Cr |
Dev Labtech Venture IPO opens on Mar 17, 2023, while Sotac Pharmaceuticals IPO opens on Mar 29, 2023. The closing date of Dev Labtech Venture IPO and Sotac Pharmaceuticals IPO is Mar 21, 2023, and Apr 03, 2023, respectively.
| Dev Labtech Venture IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Mar 28, 2023 | |
| Issue Open | Mar 17, 2023 | Mar 29, 2023 |
| Issue Close | Mar 21, 2023 | Apr 03, 2023 |
| Basis Of Allotment (Tentative) | Mar 24, 2023 | Apr 10, 2023 |
| Initiation of Refunds (Tentative) | Mar 27, 2023 | Apr 11, 2023 |
| Credit of Share (Tentative) | Mar 28, 2023 | Apr 12, 2023 |
| Listing date (Tentative) | Mar 29, 2023 | Apr 13, 2023 |
| Anchor Lockin End date 1 | May 10, 2023 | |
| Anchor Lockin End date 2 | Jul 09, 2023 |
Dev Labtech Venture IPO P/E ratio is 32.9, as compared to Sotac Pharmaceuticals IPO P/E ratio of 132.14.
| Dev Labtech Venture IPO | Sotac Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.66 | 84.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 68.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 32.9 | 132.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹42.18 Cr. | ₹122.66 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 29.68 | 53.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 0.22 | 68.34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.64 | 1.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹0.84 | ₹3.58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 22.71 | 43.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Dev Labtech Venture IPO Retail Individual Investors (RII) are offered 10,44,000 shares while in Sotac Pharmaceuticals IPO retail investors are offered 10,44,000 shares. Qualified Institutional Buyers (QIB) are offered in Dev Labtech Venture IPO and 5,70,000 shares in Sotac Pharmaceuticals IPO.
| Dev Labtech Venture IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 8,53,200 shares | |
| Market Maker Reservation | 1,12,000 shares | 1,50,000 shares |
| QIB | 5,70,000 shares | |
| NII | 10,44,000 shares | 4,28,400 shares |
| RII | 10,44,000 shares | 9,98,400 shares |
| Employee | ||
| Others | ||
| Total | 20,88,000 shares | 28,50,000 shares |
Dev Labtech Venture IPO subscribed 5.47x in total, whereas Sotac Pharmaceuticals IPO subscribed 1.60x.
| Dev Labtech Venture IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 1.00x | |
| NII (times) | 2.65x | 4.04x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 8.24x | 0.91x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 5.47x | 1.60x |
